Chagas Disease Market

Market Overview:

The 7 major Chagas disease markets reached a value of USD 1.8 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 2.6 Billion by 2035, exhibiting a growth rate (CAGR) of 3.1% during 2025-2035.

The Chagas disease market has been comprehensively analyzed in IMARC's new report titled "Chagas Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Chagas disease, also known as American trypanosomiasis, refers to a neglected tropical disease caused by the parasite Trypanosoma cruzi. It can manifest in two phases: acute and chronic. In the acute phase, which lasts for the initial weeks or months after infection, symptoms may be mild or absent. However, some individuals might experience fever, fatigue, body aches, swollen lymph nodes, and local swelling or redness at the site of the bug bite. In the chronic phase, which can last for years or even decades, the majority of patients remain asymptomatic. However, approximately 30% of infected individuals may develop serious complications, including cardiac abnormalities like cardiomyopathy, heart failure, and arrhythmias, as well as gastrointestinal issues. Diagnosing Chagas disease involves a combination of clinical evaluation, laboratory testing, and medical history assessment. The diagnosis is typically confirmed by diagnostic procedures, such as serological tests, which detect antibodies against Trypanosoma cruzi in the blood. In some cases, direct detection of the parasite through methods like polymerase chain reaction (PCR) or microscopy may be adopted. Additionally, numerous imaging techniques, including electrocardiogram (ECG) and echocardiography, are used to evaluate cardiac involvement.

The increasing cases of contact with infected triatomine bugs, which enter the body through the bite wound or mucosal membranes, such as the conjunctiva or oral cavity, are primarily driving the Chagas disease market. Besides this, the rising prevalence of several associated risk factors, including congenital transmission from an infected mother to her child, blood transfusion or organ transplantation from an infected donor, ingestion of contaminated food or beverages, etc., is acting as another significant growth-inducing factor. Furthermore, the escalating usage of antiparasitic drugs, such as benznidazole and nifurtimox, to kill the parasite as well as reduce the progression of the disease is also bolstering the market growth. Additionally, the emerging popularity of gastrointestinal complication management treatments, including dietary modifications, medications to improve motility, surgical interventions like esophageal or colonic resection, etc., for managing functional disorders related to the esophagus and colon, is further creating a positive outlook for the market. Moreover, the ongoing development of novel drug delivery systems, such as nanoparticles and liposomes, to enhance the bioavailability, targeting, and sustained release of antiparasitic medications is expected to drive the Chagas disease market in the coming years.    

IMARC Group's new report provides an exhaustive analysis of the Chagas disease market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for Chagas disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Chagas disease market in any manner.

Key Highlights:

• Around 6 to 8 million people globally are estimated to be contaminated with Trypanosoma Cruzi, the parasite that causes Chagas.
• Chagas disease is mostly found in endemic areas of 21 continental Latin American countries, where transmission is largely dependent on vector presence.
• An estimated 75 million people are at risk of infection.
• Up to one-third of persons with persistent infections acquire cardiac changes, and one in ten develop digestive, neurological, or mixed changes that may necessitate specialized care.
• Chagas disease affects around 20% of those over the age of 50.

Drugs:

Lampit (nifurtimox) is an antiprotozoal medicine used to treat Chagas disease (American Trypanosomiasis) in children aged 0 to 18 years old who weigh at least 2.5kg. Lampit, developed by Bayer, is available as yellow round, biconvex, functionally scored tablets in 30mg and 120mg dosage levels for oral use. It is specifically designed to disseminate the drug in water to aid in delivery in pediatric patients.
 

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Chagas disease market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Chagas disease market
• Reimbursement scenario in the market
• In-market and pipeline drugs
   

Competitive Landscape:

This report also provides a detailed analysis of the current Chagas disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance    
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance 
    

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the Chagas disease market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the Chagas disease market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the Chagas disease market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of incident cases (2019-2035) of Chagas disease across the seven major markets?
• What is the number of incident cases (2019-2035) of Chagas disease by age across the seven major markets?
• What is the number of incident cases (2019-2035) of Chagas disease by gender across the seven major markets?
• How many patients are diagnosed (2019-2035) with Chagas disease across the seven major markets?
• What is the size of the Chagas disease patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of Chagas disease?
• What will be the growth rate of patients across the seven major markets?
   

Chagas Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for Chagas disease drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Chagas disease market?
• What are the key regulatory events related to the Chagas disease market?
• What is the structure of clinical trial landscape by status related to the Chagas disease market?
• What is the structure of clinical trial landscape by phase related to the Chagas disease market?
• What is the structure of clinical trial landscape by route of administration related to the Chagas disease market?